<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: This study was conducted to compare the glycaemic efficacy and safety of initial combination therapy with the fixed-dose combination of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> versus <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy in drug-naive patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This double-blind study (18-week Phase A and 26-week Phase B) randomized 1250 drug-naÏve patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> [mean baseline <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c (HbA1c) 9.9%] to <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> 50/500 mg bid or <z:chebi fb="0" ids="6801">metformin</z:chebi> 500 mg bid (uptitrated over 4 weeks to achieve maximum doses of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> 50/1000 mg bid or <z:chebi fb="0" ids="6801">metformin</z:chebi> 1000 bid) </plain></SENT>
<SENT sid="2" pm="."><plain>Results of the primary efficacy endpoint (mean HbA1c reductions from baseline at the end of Phase A) are reported herein </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: At week 18, mean change from baseline HbA1c was -2.4% for <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> and -1.8% for <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy (p &lt; 0.001); more patients treated with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> had an HbA1c value &lt;7% (p &lt; 0.001) versus <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Changes in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> were significantly greater with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> (-3.8 mmol/l) versus <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy (-3.0 mmol/l; p &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Homeostasis model assessment of β-cell function (HOMA-β) and fasting proinsulin/insulin ratio were significantly improved with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> versus <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Baseline body weight was reduced by 1.6 kg in each group </plain></SENT>
<SENT sid="7" pm="."><plain>Both treatments were generally well tolerated with a low and similar incidence of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0002027'>Abdominal pain</z:hpo> (1.1 and 3.9%; p = 0.002) and diarrhoea (12.0 and 16.6%; p = 0.021) occurred significantly less with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> versus <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy; the incidence of <z:hpo ids='HP_0002017'>nausea and vomiting</z:hpo> was similar in both groups </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Compared with <z:chebi fb="0" ids="6801">metformin</z:chebi> monotherapy, initial treatment with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> <z:chebi fb="17" ids="38848">FDC</z:chebi> provided superior glycaemic improvement with a similar degree of <z:hpo ids='HP_0001824'>weight loss</z:hpo> and lower incidences of <z:hpo ids='HP_0002027'>abdominal pain</z:hpo> and diarrhoea </plain></SENT>
</text></document>